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Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the progressive decline in cognitive
functions and the deposition of aggregated amyloid b (Ab) into senile plaques and the protein tau into tangles. In addition,
a general state of oxidation has long been known to be a major hallmark of the disease. What is not known however, are the
mechanisms by which oxidative stress contributes to the pathology of AD.
Methodology/Principal Findings: In the current study, we used a mouse model of AD and genetically boosted its ability to
quench free radicals of specific mitochondrial origin. We found that such manipulation conferred to the AD mice protection
against vascular as well as neuronal deficits that typically affect them. We also found that the vascular deficits are improved
via antioxidant modulation of the endothelial nitric oxide synthase, an enzyme primarily responsible for the production of
nitric oxide, while neuronal deficits are improved via modulation of the phosphorylation status of the protein tau, which is a
neuronal cytoskeletal stabilizer.
Conclusions/Significance: These findings directly link free radicals of specific mitochondrial origin to AD-associated vascular
and neuronal pathology.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease characterized by two main pathologic hallmarks: 1)
extracellular senile plaques primarily comprised of accumulated
amyloid b (Ab) peptide and 2) intracellular neurofibrillary tangles
comprised mainly of aggregated hyperphosphorylated tau [1,2]. A
large body of evidence has demonstrated that pathologically
altered amyloid precursor protein (APP) processing is a central
player in the AD etiology [1]. Additionally, there is significant
evidence implicating oxidative stress as a key proponent in the
events leading to AD [3]. High reactive oxygen species (ROS)
levels are typically associated with the aging process, where there is
ROS overproduction in conjunction with a reduction in the
cellular antioxidant defense [4]. Most cases of AD present with
signs of oxidative damage including lipid peroxidation, protein
carbonylation, and DNA damage [5,6,7]. In addition, aspects of
Ab toxicity have been attributed to its oxidative capability. Indeed,
Ab has been shown to promote oxidation in several model systems
[8,9], increase hydrogen peroxide levels, and decrease cytochrome
C oxidase activity in the Tg2576 mouse model of AD [10]. Ab has
also been shown to induce the formation of ROS in mature
hippocampal neurons, mediated via N-methyl-D-Aspartate
(NMDA) receptors. This effect was blocked by a mitochondrial
uncoupler, indicating that the oxidative stress is of mitochondrial
origin [11]. Additionally, Ab has been shown to enter mitochon-
dria and compromise their integrity through inactivation of the
superoxide dismutase 2 (SOD-2) and a subsequent increase in
superoxide levels [12]. Ab-induced mitochondrial dysfunction has
further been linked to AD through studies showing that the genetic
reduction of SOD-2 in AD model mice can amplify multiple AD
symptoms [13,14] and lead to increased plaque deposition [15].
Conversely SOD-2 overexpression can alleviate several AD-
related symptoms, most notably the learning and memory deficits
characteristic of AD [16,17].
There is clearly a prominent role for mitochondrial superoxide
in mediating the effects of Ab on neuronal function [16]. Ab,
however, not only accumulates in neuronal parenchyma, but can
also deposit on blood vessel walls in a process referred to as
cerebral amyloid angiopathy (CAA) [18,19]. CAA has been
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AD with vascular dysfunction. This evidence includes existence of
cerebrovascular disease in the AD brain, blood brain barrier
dysfunction, and several common predisposing cerebrovascular
risk factors, such as stroke, heart disease, hypertension and
atherosclerosis [20,21,22,23]. The endothelial nitric oxide syn-
thase (eNOS) produces nitric oxide (NO) [24], which is responsible
for smooth muscle relaxation and regulation of muscle tone
[25,26,27]. During conditions of oxidative stress, production of
superoxide and its derived oxidants, induce uncoupling of eNOS
leading to the production of NOS-derived superoxide instead of
NO [28,29]. This effect is mediated primarily by Akt-dependent
phosphorylation of eNOS at serine 1177 [30,31]. The subsequent
imbalance between NO and superoxide potentiates oxidative
stress and can contribute to the onset of a variety of vascular
diseases in multiple organs [32], including the brain which is
particularly vulnerable to oxidative damage [33].
Although ROS have been well documented to contribute to
both vascular and neurodegenerative diseases, the specific source
of ROS for each particular disease is still unresolved. Given the
solid link between mitochondrial dysfunction and AD, our interest
lies in elucidating the effects of mitochondrial ROS on AD
pathology. We have already demonstrated the involvement of
mitochondrial superoxide in the learning and memory deficits
characteristic of AD [16]. Our next step was to identify whether
this effect extended systemically to the vascular system. Multiple
studies implicate mitochondrial ROS with vascular and neuronal
dysfunction. For example, using mutant mice with reduced
expression of SOD-2, Wenzel and colleagues demonstrated an
increased oxidative stress with disrupted vascular function in these
animals in relation to cardiac disease [34]. Iadecola and colleagues
used an NADPH oxidase mutant mouse and showed similar effect
of ROS on the brain vasculature [35].
Vascular homeostasis is of paramount importance for proper
neuronal function, as blood flow is required to maintain normal
neuronal physiology. AD-related blood flow deficits have been
correlated with neuronal dysfunction characteristic of the disease
[36,37]. Of particular interest is the disruption of axonal transport
during AD [38]. Axonal transport relies amongst other on a
network of cytoskeletal proteins and their associated molecules.
One such microtubule-associated protein is tau, of which the
involvement in the pathology of AD has been extensively
documented. Tau functions as a microtubule stabilizing protein
and its partial phosphorylation is required for its normal function.
Tau hyperphosporylation, however, leads to two negative
consequences: 1) loss of function by dislodging from microtubules
and subsequently destabilizing them and 2) gain of toxic function
by its capacity to sequester normal tau and other microtubule
associated proteins. Therefore there is little doubt that abnormal
tau metabolism contributes to decreased axonal transport
associated with AD [39]. Ab and oxidative stress have also been
suggested to contribute to the axonal pathology observed in AD
[40]. Less clear, however, is the mechanism by which this
contribution occurs.
AD-related vascular, mitochondrial, and neuronal dysfunctions
collectively led us to the formulation of our hypothesis that
mitochondrial superoxide is a central player in the mechanisms by
which Ab instills multiple AD pathologies, including vascular and
neuronal dysfunction. Therefore, we posited that SOD-2 overex-
pression could prevent AD-related blood flow impairments and
axonal transport deficits in the Tg2576 mouse model of AD. To
test this hypothesis, we utilized magnetic resonance imaging (MRI)
to assess cerebral blood flow and the rates of axonal transport in
the Tg2576 mice overexpressing SOD-2 at ages ranging from 4 to
16 months. Levels of eNOS and tau as well as their modulation by
phosphorylation were also determined.
Our findings suggest that Ab can exert widespread effects
partially via mitochondrial ROS impacting multiple systems, most
notably vascular and neuronal physiology. This impact may be a
key event in the etiology of AD-related blood flow and axonal
transport deficits and helps elucidate the cellular mechanisms that
precipitate neuronal degeneration. The understanding of such
events is crucial to preventing or potentially reducing neuronal
injury during AD.
Results
The effect of mitochondrial superoxide on the cerebral
blood flow in AD
Utilizing the MRI methodology arterial spin labeling (ASL), we
measured the regional cerebral blood flow (rCBF) in the cortex of
Tg2576 mice with or without SOD-2 overexpression, at ages
ranging from 4 to 16 months. We found that aged Tg2576 mice
(12 to 16 months of age) exhibited a severe blood flow deficit
compared to age-matched WT littermate controls (overall
p,0.0001) (Figure 1). Overexpression of SOD-2, and therefore
reduction of mitochondrial superoxide, resulted in a recovery of
the rCBF back to normal levels (Figure 1). Similar studies at 8
months of age, when levels of amyloid b have already begun to
increase but prior to plaque depostion, revealed the same pattern
of blood flow deficits in Tg2576 mice that was recovered upon
overexpression of SOD-2 (overall p=0.0139) (Figure S1). At 4
months of age when amyloid b pathology has not presented yet,
none of the mice studied showed a significant blood flow deficit
(Figure S1). Interestingly, SOD-2 mice exhibited a slightly lower
blood flow rate without reaching significance. This is consistent
with the notion that at a younger age, superoxide is a necessary
molecule, and therefore quenching it may result in adverse effects.
The effect of mitochondrial superoxide on eNOS function
in AD
A possible mechanism by which mitochondrial superoxide could
modulate blood flow is through modulation of eNOS function. We
Figure 1. SOD-2 overexpression improves the regional cerebral
blood flow (rCBF) deficits displayed in Tg2576 mice. A) The
graph represents the regional cerebral blood flow (rCBF) levels in 12 to
16 months old WT, SOD-2, Tg2576 and Tg2576/SOD-2 mice as
measured by MRI (ASL). Significance was assessed by a one-way
ANOVA with Dunnett’s post-test for multiple comparisons. ** p,0.01.
doi:10.1371/journal.pone.0010561.g001
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lysatesfromoldmice (12to 16 monthsofage).Becausetheamountof
eNOS protein in the sample could potentially contribute to the
amount of phosphorylation at serine 1177, we normalized phospho-
eNOS-Ser1177 levels to the amount of total eNOS protein. Also to
account for variability in loading, we measured the levels of b-actin in
the same samples and found them to be unchanged. Our data
indicated that the levels of phospho-eNOS in cortical fractions were
significantly increased in the Tg2576 mice (overall p=0.021)
(Figure 2), which correlated with the blood flow deficits observed in
the same mice. Moreover, overexpression of SOD-2 in the Tg2576
mice reduced the levels of phospho-eNOS back to those in wild-type
mice (Figure 2), which corresponded with the recovered blood flow
deficits in these same mice.
The effect of mitochondrial superoxide on axonal
transport rates in AD
Using a novel dynamic MRI imaging technique, MEMRI, we
measured in vivo axonal transport rates in the Tg2576 mice, with or
without SOD-2 overexpression, at ages ranging from 4 to 16
months. We found that aged Tg2576 mice (12 to 16 months of
age) exhibited a severe impairment in axonal transport rates
compared to the age-matched WT littermate controls (overall
p,0.0001) (Figure 3). This deficit was rescued with overexpression
of SOD-2, indicating that mitochondrial superoxide plays a key
role in the axonopathy associated with AD. A similar pattern was
observed at 8 months of age. In this age group, however, the
axonal transport rates deficits were partially rescued (overall
p,0.0001) (Figure S2). The youngest group of mice (4 months of
age) did not exhibit any axonal transport deficits, regardless of the
genotype studied (Figure S2).
The effect of mitochondrial superoxide on tau
hyperphosphorylation in AD
During AD, axonal transport rate dysfunction has been in part
associated with microtubule destabilization, following hyperpho-
sphorylation of the microtubule-associated protein tau [41]. We
measured the levels of phospho-tau at multiple epitopes (199, 202,
205, 231 and 356) but could not detect hyperphosphorylation of
tau at these sites in Tg2576 mice (data not shown). We detected
tau hyperphosphorylation at the serine 262 site (located in the
microtubule binding domain of tau), in olfactory bulb homoge-
nates of aged mice (12 to 16 months). Because the amount of tau in
the sample could potentially contribute to the amount of
phosphorylation at serine 262, we normalized phospho-tau levels
to the amount of total tau protein. Also to account for variability in
loading, we measured the levels of b-actin in the same samples and
found them to be unchanged. We observed a significant increase
in the levels of phospho-tau (ser262) in the olfactory bulbs of
Tg2576 mice (overall p=0.0099) (Figure 4). This increase was
recovered back to wildtype levels upon SOD-2 overexpression
(Figure 4), coinciding with the recovery from axonal transport
deficits in these animals.
Discussion
Herein we have shown that reducing mitochondrial superoxide
by SOD-2 overexpression ameliorated cerebral blood flow deficits
and axonal transport deficits typically exhibited by Tg2576 mice.
The reduction of mitochondrial superoxide also resulted in a
concomitant reduction of phosphorylation of eNOS at serine
1177, as well as phosphorylation of tau at serine 262. Utilizing the
same mouse model, we have previously shown that SOD-2
overexpression did not alter the elevated levels of Ab during AD
but resulted in a decrease in the Ab42/Ab40 ratio, indicative of an
Ab pool less favorable for aggregation. SOD-2 is the main
superoxide scavenger in mitochondria. Therefore, we interpret
our data as direct in vivo evidence that mitochondrial superoxide is
a key player in AD-related vascular and neuronal dysfunction,
working as a downstream effector of Ab, possibly affecting Ab
processing.
Ab, blood flow and eNOS
One of the earliest events in the development of AD pathology
is a progressive elevation of Ab which eventually is secreted and
accumulates as senile plaques, not only on brain parenchyma but
also within the vasculature [1,42]. In the Tg2576 mouse model of
AD, Ab has been shown to deposit within the vasculature
beginning at approximately 9 months of age and continuing as
aging ensues [42]. Ab vascular deposition has been linked to
vascular dysfunction, specifically blood flow deficits, occurring
during the development of AD [37]. In this particular mouse
model of AD, soluble Ab levels are elevated beginning at 6 months
of age, well before vascular Ab deposition [42]. Similar to the
wealth of studies implicating soluble Ab in AD-related toxicity, it
has been suggested that soluble Ab plays a role in the blood flow
deficits as well, possibly contributing to the early progression of
AD via a systemic effect on the vasculature. Based on this
hypothesis, Shin and associates measured cerebral blood flow in 8
Figure 2. SOD-2 overexpression prevents increases in phospho-eNOS-ser1177 in Tg2576 mice. A) Graph represents quantification of the
levels of phospho-eNOS-ser1177 normalized to total eNOS from 12 to 16 months old cortical homogenates of WT, SOD-2, Tg2576 and Tg2576/SOD-2
mice. Significance was assessed by one way ANOVA with Dunnett’s post-test for multiple comparisons. *p,0.05. B) Representative Western blot of
phospho-eNOS-Ser1177, total eNOS and b-actin from cortical homogenates of 12 to 16 months old WT, SOD-2, Tg2576 and Tg2576/SOD-2 mice.
doi:10.1371/journal.pone.0010561.g002
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flowmetry through an intact skull [37]. They confirmed the blood
flow deficits in the aged group, but failed to record any differences
in cerebral blood flow and vascular physiology between 8 month-
old Tg2576 mice and their wild-type littermate controls [37]. In
our studies, we utilized a non-invasive MRI technique to measure
cerebral blood flow in Tg2576 mice and confirmed that it is
significantly deficient post vascular plaque deposition (12–16
months of age). However, in contrast to the previous study, we
were able to detect a significant deficiency in cerebral blood flow at
8 months of age, prior to Ab vascular deposition. This discrepancy
could be due to the differences in imaging modalities utilized, as
Figure 3. SOD-2 overexpression improves the axonal transport deficits displayed by Tg2576 mice. A) The graph represents the rates on
axonal transport as measured in vivo by MEMRI in 12 to 16 months old WT, SOD-2, Tg2576 and Tg2576/SOD-2 mice. Significance was assessed by a
one-way ANOVA with Dunnett’s post-test for multiple comparisons. ** p,0.01. B) Representative MR images with a pseudo-color overlay showing
manganese accumulation in the region of interest (indicated by an arrow) in the olfactory bulb of 12 to 16 months old WT, SOD-2, Tg2576 and
Tg2576/SOD-2 mice. Top row images represent the first repetition of the scan, where axonal transport of manganese has not started yet. Bottom row
images represent the last repetition of the scan, where most of the manganese has already accumulated in the region of interest. Note that for the
Tg2576 mice, no manganese accumulated in the region of interest which is indicative of deficient axonal transport. In the Tg2576/SOD-2 mice,
accumulation of manganese is intact, indicating recovered axonal transport. The two images from each animal are on the same brightness scale.
doi:10.1371/journal.pone.0010561.g003
Figure 4. SOD-2 overexpression prevents increases in phospho-tau-ser262 in Tg2576 mice. A) Graph represents quantification of the
levels of phospho-tau-ser262 normalized to total tau from 12 to 16 months old olfactory bulb homogenates of WT, SOD-2, Tg2576 and Tg2576/SOD-2
mice. Significance was assessed by one way ANOVA with Dunnett’s post-test for multiple comparisons. *p,0.05; **p,0.01. B) Representative
Western blot of phospho-tau-Ser262, total tau and b-actin from olfactory bulb homogenates of 12 to 16 months old WT, SOD-2, Tg2576 and Tg2576/
SOD-2 mice.
doi:10.1371/journal.pone.0010561.g004
Superoxide and AD Pathology
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previously noted differences within the Tg2576 mice depending
upon where the images were acquired (data not shown). We also
showed that reducing mitochondrial superoxide by SOD-2
overexpression led to improvement of the blood flow deficits in
Tg2576 mice at both age points, indicating that mitochondrial
superoxide exerts a global impact on the vascular system, early on
during soluble Ab elevation. The debate remains whether excess
mitochondrial superoxide contributes to Ab elevation or whether
Ab elevation occurs first and causes an increase in superoxide
levels. We and others recently performed behavioral and
biochemical studies using a similar animal model and demon-
strated that SOD-2 overexpression improved AD-related learning
and memory deficits without reducing the elevated levels of Ab
[16,17]. These studies suggest that mitochondrial superoxide
exerts its effect downstream of Ab. In our previous study, however,
we demonstrated that SOD-2 overexpression causes a reduction in
the Ab42/Ab40 ratio, thereby modifying the Ab pool towards a
less amyloidogenic composition [16]. The latter suggests that
mitochondrial superoxide can also affect Ab processing. Addition-
ally, Guglielmotto and associates demonstrated that brain
hypoperfusion can lead to increased b-secretase activity (and
therefore increased Ab levels) via hypoxia-induced ROS overpro-
duction from mitochondria [43]. Together these studies illustrate
an amplification loop through which Ab and mitochondrial
superoxide potentiate each other’s pathological effect on vascular
and brain function during AD.
We also demonstrated that Tg2576 mice exhibit an increased
phosphorylation of eNOS at serine 1177. eNOS expression has
been shown to be decreased in the brains of AD patients [44]. Its
activity, however, has not yet been measured. eNOS activity is
regulated mainly via phosphorylation, with two most prominent
regulatory sites: threonine 495, which is inhibitory [45] and serine
1177, which is permissive [46]. Our data therefore supports
increased activation of eNOS in the aged (12–16 months old)
Tg2576 mice. Most importantly, eNOS phosphorylation at serine
1177 has been shown to promote increased superoxide production
from the enzyme [28], thereby contributing to the existing
oxidative stress in these animals. Increased superoxide production
from eNOS also means that nitric oxide production is compro-
mised. This imbalance between nitric oxide and superoxide levels
may be causative of the observed blood flow deficits, as suggested
from previous studies [32]. In support of this possibility, SOD-2
overexpression returns the eNOS phosphorylation status back to
normal. eNOS phosphorylation at serine 1177 is mediated by Akt
[31], which has been extensively shown to be modulated by
oxidative stress. Our data support previous reports and also
specifically implicate mitochondrial superoxide in Akt-dependent
eNOS phosphorylation at serine 1177. Collectively, these studies
suggest that mitochondrial superoxide plays a key role in the
initiating events of the AD-related vascular deficits.
Ab, axonal transport and tau
We have previously shown that the Tg2576 mouse model of AD
exhibits severe deficits in axonal transport rates beginning at 7
months of age and progressively worsening in parallel to the age-
and AD-related increases in Ab levels [47]. We chose to perform
our experiments in the olfactory system because it is one of the first
systems affected during AD, APP/Ab pathology occurs in the
olfactory bulb [47], and because of the ease and non-invasive
possibility of manganese introduction via a nasal lavage. In the
current study, we confirmed the early occurrence of axonal
transport rates deficits in the 8-month old Tg2576 mice as well as
the maintenance of these deficits in mice12 to 16 months of age.
We further extended the use of this MEMRI technique to assess
whether SOD-2 overexpression would alleviate these symptoms.
We found that the reduction of mitochondrial superoxide
significantly prevented the deficits in axonal transport rates in
the Tg2576 mice, indicating that ROS of mitochondrial origin are
a key factor in transducing the impact of Ab on neuronal
physiology.
Given that SOD-2 functions with manganese as an essential
cofactor, it is conceivable that SOD-2 transgenic mice may exhibit
baseline positive contrast enhancement in T1-weighted MRI
images. To ensure that this was not a confounding factor in the
interpretation of our data, we measured the T1 and T2 values in 2
month-old wild-type, SOD-2, Tg2576, and Tg2576/SOD-2 mice
at baseline, in the cortex, hippocampus and olfactory bulb. Our
data showed no significant differences in T1 and T2 values
regardless of the genotype studied (Figure S3) indicating that
endogenous manganese does not significantly contribute to signal
enhancement. Additionally, our MEMRI experiments were
designed to measure axonal transport rates as opposed to absolute
transport. Therefore, even in the event of a baseline signal
enhancement in SOD-2 mice, the rate of change of signal
intensity, which is representative of axonal transport rates, should
not be affected.
One pathway that mitochondrial ROS could affect to alter
axonal transport is through the microtubule-associated protein
tau. Tau stabilizes microtubules through binding and is essential to
the integrity of axonal transport [48]. Reducing endogenous levels
of total tau has been shown to ameliorate the Ab-induced
pathology [49], indicating that it plays a role downstream of Ab
during the events leading to AD. Another theory about the
involvement of tau in AD pertains to its phosphorylation status.
During the progression of AD, there is extensive hyperpho-
sphorylation of tau that causes it to detach from the microtubule
network. This leads to the destabilization of microtubules resulting
in axonal transport deficits [50]. Hyperphosporylation of tau also
has been shown to contribute to neuronal death [51]. We
specifically found an increase in the phosphorylation of tau at
serine 262 in olfactory bulb homogenates of Tg2576 mice. This
phosphorylation site is located within the microtubule binding
domain of tau. Phosphorylation of tau is returned back to normal
with SOD-2 overexpression, indicating that mitochondrial super-
oxide also affects axonal transport through tau dysfunction.
Additionally, to extend the pathophysiological significance of such
results to areas of the brain that are more directly relevant to
cognitive deficits observed in AD, we measured the levels of
phosphorylated tau at serine 262 in cortical homogenates of aged
mice, which include frontal cortex, hippocampus and amygdala.
We observed a significant increase in the levels of phopshorylated
tau (serine 262) in Tg2576 mice compared to controls (overall
p,0.001) (Figure S4). This increase was recovered back to
wildtype levels upon SOD-2 overexpression, suggesting that
mitochondrial superoxide contributes to tau pathology not only
in the olfactory bulb, but also extends to the learning and memory
centers of the brain. It is not clear, however, what are the
mechanisms of such an effect. An attractive possibility can be
related to the blood flow deficits in the first portion of this study.
We have demonstrated an effect of mitochondrial ROS on blood
flow which is known to affect glucose metabolism. According to
this scheme, decreased blood flow lead to a decrease in glucose
metabolism, and particularly a reduction in the sugar O-GlcNAC.
O-GlcNACylation is a well documented post-translational mod-
ification of tau that competes for the same sites as its
phosphorylation [52]. Therefore, decreased O-GlcNACylation of
tau results in its increased phosphorylation due to lack of binding
Superoxide and AD Pathology
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decreased axonal transport rates. Therefore, it is possible that
mitochondrial ROS affect nerve function via a global effect on the
vasculature. This is not uncommon, as blood flow is known to be
required for the integrity of neuronal function. An alternative
explanation is that mitochondrial ROS exert a direct effect on the
signaling pathway leading to hyperphosphorylation of tau. For
example, the glycogen synthase kinase 3 beta (GSK-3b), one of the
major kinases modulating tau phosphorylation has been shown to
be inhibited by antioxidant treatment [53], indicating that ROS
activate the enzyme and result in increased phosphorylation of tau.
Further experiments are required to clarify whether ROS affect
tau phosphorylation directly or via their effect on blood flow.
Regardless of the mechanism however, it is clear that mitochon-
drial superoxide plays a central role in neuronal pathology as
exemplified by axonal transport deficits.
Concluding remarks
Although oxidative stress has long been known to contribute to
AD pathology both in its early and late stages, the mechanisms of
such contribution remain unclear. One hypothesis implicates Ab
as the initiator of AD. Ab is a powerful oxidant and therefore, as
its levels are progressively elevated during the progression of the
disease, so are the levels of ROS. On the other hand, with the
exception of the genetic cases, sporadic AD is a disease of the
elderly and oxidative stress is known to occur during physiological
aging in the absence of elevated Ab levels. Therefore, oxidative
stress could also be contributing to the initiating factors of AD. We
would like to emphasize the important issue of the production
source of ROS. Although oxidative stress has been shown to
contribute to the pathology of aging, we have specifically shown
that mitochondrial ROS do not participate in synaptic plasticity
and memory impairments occurring in aged mice [54]. One
possible reason is the selective nature of the inner mitochondrial
membrane which does not allow superoxide leakage. During AD,
mitochondrial dysfunction is very well documented and thus, it is
possible that mitochondrial superoxide leaks across the mitochon-
drial membrane. The vascular endothelium and the brain both
have high energy demands and contain high levels of mitochon-
dria, and are therefore more vulnerable to mitochondrial ROS,
especially when their levels go out of balance. Although various
antioxidant therapies have been attempted to treat AD, they were
only mildly effective, perhaps because of their non-specific nature.
Our data provides strong evidence that mitochondrial-derived
superoxide acts possibly as a mediator and/or potentiator of the
toxic effects of Ab systemically on the vasculature and regionally
on nerve physiological functioning. Therefore, mitochondria are
an excellent target candidate for antioxidant drug development to
treat AD.
Methods
1. Transgenic Mouse Lines
We crossed male Tg2576 AD mice with SOD-2 overexpressing
females and obtained progeny of WT, SOD-2, Tg2576 and Tg2576/
SOD-2 mice. Both parent transgenic lines have been previously
described [55,56]. Briefly, the Tg2576 mouse carries the Swedish
mutant human amyloid precursor protein (APP) under the hamster
prion promoter and the SOD-2 transgenic mouse overexpresses the
mitochondrial superoxide dismutase under the b-actin promoter.
Experiments were performed at 4, 8, and 12–16 months of age.
Genotypes were determined by PCR using tail DNA with the
following primers: 59-CTG-ACC-ACT-CGA-CCA-GGT-TCT-
GGG-T-39 and 59-GTG-GAT-AAC-CCC-TCCCCC-AGC-CTA-
GAC-CA-39 for APP; and 59-CAC-AAG-CAC-AGC-CTC-CCA-
G-39 and 59-CGC-GTT-AAT-GTG-TGG-CTC-C-39 for SOD-2.
All mice were housed at Baylor College of Medicine’s transgenic
mouse facility in compliance with the National Institutes of Health
guidelines for Care and Use of Laboratory Animals. The mouse
facility is kept on a 12-hour light–dark cycle, with a regular feeding
and cage-cleaning schedule. All experiments were conducted and
approved by Baylor College of Medicine’s IACUC.
2. MRI Studies
A. Animal preparation. All mice were initially anesthetized
with 5% isoflurane in oxygen. Following transfer to the animal
holder within the magnet, anesthesia was maintained at 1.5–2%
isoflurane in oxygen. The animal’s temperature was held constant
at 37uC using an air heating system and monitored with a rectal
probe (Small Animal Instruments (SAI), Inc. (Stony Brook, NY)).
Respiratory rates were also monitored utilizing a respiratory probe
and monitored during the entire imaging session ((Small Animal
Instruments (SAI), Inc. (Stony Brook, NY)). All imaging protocols
were conducted utilizing a 9.4 T, Bruker Avance Biospec
Spectrometer, 21 cm bore horizontal imaging system with a
35 mm volume resonator (Bruker BioSpin, Billerica, MA).
B. In vivo axonal transport measurements. We measured
axonal transport rates in vivo utilizing a Manganese Enhanced
MRI (MEMRI) protocol as we have described previously [47].
Briefly, a concentrated solution of MnCl2 (0.77 g/ml) was pipetted
into the nasal cavity of the mouse at a total of 4 ml( 2ml/naris).
Mice were allowed to recover for 45 minutes on a heating pad,
allowing the loading of Mn
2+ into the olfactory receptor neurons
located in the olfactory epithelium. The mice were then sedated
with isoflurane and loaded into the magnet. The zero time point
for imaging was at 60 minutes post Mn
2+ exposure. Spin lattice
(T1)-weighted, spin-echo 2D data sets were acquired of the mouse
brain using a multi-slice/multi-echo 2D imaging protocol with the
following parameters: matrix dimensions =1286128; FOV=3.0
cm63.0; slice thickness=1 mm; repetition time (TR)=504.1 ms;
echo time (TE) =8.2 ms; number of averages (NA) =2; number of
repetitions=15; time per image=2 min. Four axial slices were
selected with the first slice aligned with the leading edge of the
olfactory bulb. In all studies, slice 2 of the 4 slices was assayed for
axonal transport in a region of interest (ROI) selected in the dorsal
lateral portion of the olfactory bulb. Changes in the signal intensity
of this ROI were measured using Bruker’s Paravision software and
plotted using Microsoft Excel and GraphPad Prism (GraphPad
Software, Inc., (LaJolla, CA)). All signal intensities were
normalized to non-enhanced muscle outside of the brain. A least
squares method was used to determine the change in signal
intensity over time, reflective of the rate of transport of Mn
2+.
C. Cerebral blood flow measurements. We measured the
regional cerebral blood flow (rCBF) with the MRI imaging protocol,
arterial spin labeling (ASL). We utilized a flow alternating inversion
recovery-echo planar imaging (FAIR-EPI) protocol with the following
imaging parameters: matrix dimensions=64664; FOV=1.5 cm61.5
cm; slice thickness=1.5 mm; TR=7555.377 ms; TE=16.73 ms;
NA=1; number of repetitions=1; flip angle=90; inversion recovery
time (TIR) =18.25 ms; number of TIR values=16; increment of
TIR=500 ms; inversion slab thickness (for the selective inversion) =5
mm. In order to determine the proper reproducible section location, a
standard scan of the whole brain was obtained with 16 coronal slices
spanning from the leading edge ofthe olfactory bulb to the trailing edge
of the cerebellum. The slice of interest was determined as the first
coronal section where the rostral portion of the hippocampus appears.
The location of this particular slice was noted and used in the blood
flow protocol. The ROI was manually selected in the entire cortex
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T1 values from the scans with selective and non-selective inversions
were calculated using the t1invacq function in Bruker’s paravision 4.0.
Blood flow was calculated using the following formula: rCBF=l(1/
T1 selective21/T1 non-selective)w h e r el is the blood brain partition
coefficient, equivalent to 0.9 (or 90 g per 100 g) for the mouse brain.
Data was plotted using GraphPad Prism (GraphPad software, Inc. (La
Jolla, CA)).
D. T1 and T2 measurements. We measured the T1 and spin-
spin relaxation rates (T2) values in 2 months old WT, SOD-2,
Tg2576 and Tg2576/SOD-2 animals at baseline, in the cortex,
hippocampus and olfactory bulb. In order to determine the proper
reproducible section location, a standard scan of the whole brain was
obtained with 16 coronal slices spanning from the leading edge of the
olfactory bulb to the trailing edge of the cerebellum. The slice of
interest for the cortex/hippocampus was determined as the first
coronal section where the rostral portion of the hippocampus
appears, matching the section chosen for the rCBF studies. The slice
of interest for the olfactory bulb was chosen to match the slice
selected for the axonal transport studies. To acquire the T1 values,
the brain was imaged using a 2D spin echo sequence with a dynamic
TR parameter: TR =326.38, 928.309, 1949.379, 7500 ms.
Other parameters included TE =6.6 ms, FOV=2.5 cm, slice
thickness=1 mm, NA=1, matrix=1286128. T2 weighted images
were acquired using the following settings: TR=1000 ms,
TE=10.3, 20.6 ms, FOV=3.0 cm, slice thickness=1 mm,
NA=1, matrix=1286128. The olfactory bulb was imaged using
the same parameters. Analysis of MR images was conducted using
Bruker’s paravision 4.0. For the cortex and hippocampus, the ROIs
were drawn manually in each hemisphere. For the olfactory bulb,
only the right side was used, due to the presence of the chemical shift
artifact on the left side. ROIs for the cortex and olfactory bulb
matched the ones selected in the CBF and MEMRI studies,
respectively. The ROI for the hippocampus covered the entire
surface of the rostral hippocampus, in the slice selected, as described
above. The T1 recovery and T2 decay values were calculated for
each brain region and plotted using GraphPad Prism (GraphPad
s o f t w a r e ,I n c .( L aJ o l l a ,C A ) ) .
3. Brain Sample Preparation
Mice were sacrificed by cervical dislocation then their brains were
extracted fresh on ice. The left hemispheres were further dissected to
obtain the olfactory bulb and cortex. The olfactory bulb was
homogenized by sonication in 250 ml of Tris buffered saline (TBS)
containing protease and phosphatase inhibitors and the cortex was
homogenized with a glass dounce homogenizer in 2 ml of the same
buffer (137 mM NaCl, 20 mM Tris, pH 7.6, 1:100 of each of
protease inhibitors cocktail, phosphatase inhibitor cocktail I and
phosphatase inhibitor cocktail II (Sigma-Aldrich)). Homogenates
were centrifuged at 5000 g for 5 minutes, and then the supernatants
were aliquoted and saved at 280uC until further use.
4. Immunoblotting
Total protein from brain samples were measured with the DC
assay (Bio-Rad Laboratories (Hercules, CA)), and equally loaded
and separated by SDS/PAGE. Protein samples were then
transferred onto a nitrocellulose membrane that was blocked with
a TBS solution containing 2.5% w:v milk, 2.5% w:v bovine serum
albumin, 0.1% Tween 20 and 0.05M NaF. The membranes were
then probed with 1:250 anti-phospho-262-tau antibody (Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA)), 1:5000 anti-tau
(Dako North America, Inc. (Carpinteria, CA)), 1:1000 anti-
phospho-eNOS-1177 (Cell Signaling Technology, Inc. (Danvers,
MA)), 1:1000 anti-eNOS (Cell Signaling Technology, Inc.
(Danvers, MA)) or 1:10000 anti-b-actin (Sigma-Aldrich (St. Louis,
MO)). This initial incubation was then followed by a horseradish
peroxidase-conjugated secondary antibody (Promega Corporation
(Madison, WI)) against mouse IgG (for actin) and against rabbit
IgG (for all remaining). Development was achieved by autoradi-
ography in a Kodak X-omat 2000A processor using ECL (GE
Healthcare Life Sciences (Piscataway, NJ)) or Super Signal
(Thermo Fisher Scientific (Rockford, IL)) as needed.
For band analysis, films were scanned using an EPSON scanner
and then band density calculated using Image J 1.38x (National
Institutes of Health, USA). Data was plotted using GraphPad
prism (GraphPad Software, Inc. (La Jolla, CA)).
5. Statistics
In all experiments mentioned above, statistical analyses were
carried out in Prism (GraphPad Software, Inc. (La Jolla, CA)).
Statistical significance was calculated using a one way analysis of
variance (ANOVA) followed by Dunnett’s post-test for multiple
comparisons. A p-value of 0.05 or less was considered statistically
significant.
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Supporting Information
Figure S1 Regional cerebral blood flow measurements at 4 and
8 months of age. A) The graph represents the cerebral blood flow
levels in 4 months old WT, SOD-2, Tg2576 and Tg2576/SOD-2
mice as measured by MRI (ASL). No differences in blood flow
levels between the different genotypes are observed. B) The graph
represents the cerebral blood flow levels in 8 months old WT,
SOD-2, Tg2576 and Tg2576/SOD-2 mice as measured by MRI
(ASL). Tg2576 mice exhibit a significant deficit in their blood flow
that is recovered by SOD-2 overexpression. Significance was
assessed by a one-way ANOVA with Dunnett’s post-test for
multiple comparisons. **p,0.01.
Found at: doi:10.1371/journal.pone.0010561.s001 (0.87 MB
TIF)
Figure S2 Axonal transport rates measurements at 4 and 8
months of age. A) The graph represents the axonal transport rates
measured in vivo by MEMRI in 4 months old WT, SOD-2,
Tg2576 and Tg2576/SOD-2 mice. No differences in axonal
transport rates between the different genotypes are observed. B)
The graph represents the axonal transport rates measured in vivo
by MEMRI in 8 months old WT, SOD-2, Tg2576 and Tg2576/
SOD-2 mice. Tg2576 mice exhibit a significant deficit in their
axonal transport rates that is at least partially recovered by SOD-2
overexpression. Significance was assessed by a one-way ANOVA
with Dunnett’s post-test for multiple comparisons. **p,0.01.
Found at: doi:10.1371/journal.pone.0010561.s002 (0.85 MB
TIF)
Figure S3 SOD-2 overexpression and the APP-Swedish muta-
tion do not affect the T1 recovery and T2 decay times. A-C)
Graphs represent the T1 recovery times measured in the cortex,
hippocampus and olfactory bulb of 2 months old WT, SOD-2,
Tg2576 and Tg2576/SOD-2 mice. D-F) Graphs represent the T2
decay measured in the cortex, hippocampus and olfactory bulb of
2 month old WT, SOD-2, Tg2576 and Tg2576/SOD-2 mice.
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Figure S4 SOD-2 overexpression prevents increases in phospho-
tau-ser262 in the brain of Tg2576 mice. A) Graph represents
quantification of the levels of phospho-tau-ser262 normalized to
total tau from 12 to 16 month old brain homogenates of WT,
SOD-2, Tg2576 and Tg2576/SOD-2 mice. Significance was
assessed by one way ANOVA with Dunnett’s post-test for multiple
comparisons. **p,0.01. B) Representative Western blot of
phospho-tau-Ser262, total tau and b-actin from brain homoge-
nates of 12 to 16 month old WT, SOD-2, Tg2576 and Tg2576/
SOD-2 mice.
Found at: doi:10.1371/journal.pone.0010561.s004 (0.37 MB TIF)
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